Comparative Pharmacology
Head-to-head clinical analysis: BRENZAVVY versus INVOKANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRENZAVVY versus INVOKANA.
BRENZAVVY vs INVOKANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brenzavvy (bexagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It inhibits SGLT2 in the proximal renal tubule, reducing glucose reabsorption and increasing urinary glucose excretion, thereby lowering blood glucose levels. It also promotes osmotic diuresis and may improve cardiovascular and renal outcomes through hemodynamic and metabolic effects.
Sodium-glucose cotransporter 2 (SGLT2) inhibitor; reduces renal glucose reabsorption, increasing urinary glucose excretion.
Recommended dose: 1 tablet (200 mg finerenone) orally once daily.
100 mg orally once daily, before the first meal of the day; may increase to 300 mg once daily if tolerated and eGFR is adequate.
None Documented
None Documented
The terminal elimination half-life is approximately 12-15 hours in patients with normal renal function, supporting once-daily dosing.
Terminal elimination half-life is 10.6 hours (range 9.5–12.5 h) in healthy subjects; allows once-daily dosing. Half-life increases to 16 hours in moderate renal impairment and 22 hours in severe renal impairment.
Approximately 65% of the dose is excreted renally as unchanged drug, and about 35% is eliminated via biliary/fecal routes as metabolites.
Primarily excreted unchanged in urine (33%) and feces (52%) as parent drug and glucuronide metabolites; renal clearance accounts for 70% of total clearance, with 51% renally excreted as unchanged drug.
Category C
Category C
SGLT2 Inhibitor
SGLT2 Inhibitor